Article info

Protocol
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19

Authors

  • Mohammad Bosaeed Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaDepartment of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Ahmad Alharbi Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Mohammad Hussein Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Mohammed Abalkhail Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Khizra Sultana Department of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Abrar Musattat Department of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Hajar Alqahtani Department of Pharmaceutical Care, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Majid Alshamrani Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Ebrahim Mahmoud Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Adel Alothman Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Abdulrahman Alsaedy Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Omar Aldibasi College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaBiostatistics and Bioinformatics, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Khalid Alhagan Department of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Abdullah Mohammed Asiri Department of Nursing, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Sameera AlJohani College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaDepartment of Pathology and Laboratory Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Majed Al-Jeraisy College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaDepartment of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Ahmed Alaskar College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaDepartment of Oncology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mohammad Bosaeed; dr.bosaeed{at}live.com
View Full Text

Citation

Bosaeed M, Alharbi A, Hussein M, et al
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19

Publication history

  • Received December 2, 2020
  • Revised March 3, 2021
  • Accepted March 11, 2021
  • First published April 14, 2021.
Online issue publication 
June 20, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.